Artios Pharma Ltd, a UK clinical-stage company with products to kill cancer cells by blocking their ability to repair damaged DNA, has raised $115 million in an oversubscribed Series D financing. The round was co led by founding investor SV Health Investors and new investor RA Capital Management. The funds will be used to advance two small molecule drugs against large cancers. The first, alnodesertib, is an inhibitor of the ATR protein which is involved in DNA repair, and the second is ART6043, an inhibitor of the DNA repair enzyme DNA polymerase theta (Pol theta).
